Theratechnologies Stock Plummets On Disappointing Q1 Earnings, Full Year Forecast: Retail Sentiment Sours

Shares of Theratechnologies Inc. (THTX) tumbled 16% on Wednesday after the company’s first-quarter earnings fell below Wall Street estimates.

Theratechnologies reported a revenue of $19.05 million, marking a growth of 17.2% from the corresponding period last year, but below an analyst estimate of $20.43 million, according to FinChat data.

Revenue from the sales of Egrifta SV, used to treat HIV-related excess visceral abdominal fat, jumped by nearly 45% due to higher unit sales and higher selling price.

Unit sales rose as the company rebuilt its distributor and pharmacy inventories following a supply disruption resulting in a one-time loss of six to seven weeks of sales.

CEO Paul Lévesque said that while the number is mainly related to reloading the pipeline following an end to the temporary supply disruption, the fundamentals of the business and specifically demand for Egrifta SV remains very strong.

He added that the HIV portfolio led by the Egrifta franchise will continue to remain an “engine of growth” for years.

The company reported positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $2.3 million, compared to a loss of $247,000 in the same quarter of 2024, but below an estimated $3.93 million.

For the fiscal year 2025, the company estimates revenue in the range of $80 million to $83 million and adjusted EBITDA to be between $10 and $12 million, below an estimated $21.16 million.

On Stocktwits, retail sentiment around Theratechnologies fell from ‘neutral’ to ‘bearish’ territory, coupled with ‘extremely low’ message volume over the past 24 hours.

THTX shares have been down nearly 30% this year and over 16% over the past 12 months.

Also See: Ford Stock In Spotlight After Bernstein Downgrade, Price Target Cut: Retail Stays Pessimistic

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on